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Chemotherapy is widely used in the management of advanced
breast cancer, although there have been no randomized controlled
trials to assess the benefits of chemotherapy as compared with best
supportive care, in terms of survival or quality of life. Disease
response, measured in terms of tumour shrinkage, is observed in
between 40% and 60% of cases during controlled clinical trials
(Benner et al, 1994; Leonard et al, 1995). This reduction in tumour
bulk has been shown to be associated with relief of symptoms and
improvement in quality of life (Baum et al, 1980). Furthermore, in
individual cases, there is little doubt that chemotherapy prolongs
survival by months or even years. If chemotherapy were without
toxicity such benefits would be considered worthwhile even if
only a small proportion of patients experienced them. The reality,
however, is that a considerable proportion of patients experience
toxicity without gaining benefit. 
Despite the lack of evidence regarding the benefit of palliative
chemotherapy in advanced breast cancer, there is some agreement
among oncologists regarding the reasons for prescribing treat-
ment. These goals include potential prolongation of life, the relief
of cancer-related symptoms and the prevention of symptoms/
complications associated with the disease (Rubens et al, 1992).
Additionally, chemotherapy may be prescribed to maintain a
patient’s sense of hope, to reduce anxiety or because the patient
expresses a wish to continue with treatment (Markman, 1997). In
some cases chemotherapy is administered to avoid difficult
communication situations (Porsoltz and Tannock, 1993). 
Oncologists consider a range of factors when deciding whether
or not to offer palliative chemotherapy, including objective disease
and treatment-related factors and more subjective patient-related
factors. Disease-related factors include sites of metastases and pace
of disease, whereas treatment-related factors incorporate disease
response to previous treatments and associated toxicity (Stoll,
1990). Patient-related factors influencing management choice
include the patient’s chronological and physical age, social support
networks, and the interests of the patient’s family (Stoll, 1990). In
situations where the patient’s prognosis is poor, and where less
agreement exists among specialists regarding the appropriate
course of action, the decision process will often be driven by these
more subjective value judgements (Maher and Jeffries, 1990). 
The extent to which different disease, treatment and patient-
related factors predict the outcome of treatment with palliative
chemotherapy for advanced breast cancer is largely unknown.
Initial disease-free interval and abnormal liver function tests/liver
metastases have been identified as important prognostic factors
(Namer et al, 1990; Falkson et al, 1991; Gregory et al, 1993) but
evidence relating to other disease and patient characteristics is
conflicting. Preliminary work has been undertaken to identify the
factors predicting patient-reported benefit from first-line palliative
chemotherapy using a simple global measure of well-being
(Ramirez et al, 1998). High levels of psychological distress and
the presence of a dry mouth prior to treatment were found to
predict feeling worse after treatment. These 2 factors as well as
pre-treatment lack of energy, breathlessness and the presence of
liver metastases predicted patients failing to complete treatment
either because they died or stopped attending hospital. 
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doi: 10.1054/ bjoc.2001.1733, available online at http://www.idealibrary.com on  http://www.bjcancer.comThe paucity of evidence for survival or quality of life benefits of
chemotherapy compared with supportive care and for factors
which may predict benefit from palliative chemotherapy, means
that oncologists offer palliative chemotherapy to women with
advanced disease based on empirical grounds. In this context there
is a lack of information regarding the factors influencing
oncologists’ decision-making in the management of advanced
breast cancer. This study aimed to elicit oncologists’ views of the
goals of palliative chemotherapy and the relative importance
assigned to tumour, treatment- and patient-related factors in 
decision-making regarding palliative chemotherapy for patients
with advanced breast cancer. 
Oncologists’ views of the goals of chemotherapy were exam-
ined according to a model of decision-making. A theoretically
driven approach was adopted in order to improve comparability
across goals (the same questions were asked in relation to each
goal) and also to explain why clinicians make certain decisions.
The Subjective Expected Utility (SEU) theory of decision-making
was selected (Edwards, 1954; Tversky, 1967). Using this approach
2 key factors believed to influence decision-making were exam-
ined. Firstly, does the clinician believe that each of the goals of
chemotherapy is achievable (e.g. does the clinician believe that
chemotherapy can prolong life)? Secondly, how valuable or
important is that goal to the clinician (e.g. how worthwhile is it to
prolong the patient’s life)? This approach enabled the assessment
of the relative priority of the separate goals when making decisions
regarding chemotherapy. It also enabled the separate examination
of the perceived effectiveness (expectancy) and perceived value 
(utility) associated with each of the goals. This theory has been
applied previously to investigate health-related decision-making,
including patient decisions regarding treatment for breast cancer
(Stanton et al, 1998). 
PARTICIPANTS AND METHODS 
All the specialist registrars and consultants in oncology working at
two cancer centres were invited, by letter, to participate in the
study. Of the 40 oncologists approached, 30(75%) agreed to partic-
ipate. Those who declined did so either because they could not
spare the time or because they were not involved in the treatment
of patients with advanced breast cancer. All participating clini-
cians were currently involved in the treatment of women with
advanced breast cancer. The participants comprised 20 specialist
registrars (3 medical oncologists, 17 clinical oncologists) and 10
consultants (3 medical oncologists, 7 clinical oncologists). The
median age of the clinicians was 35.5 years (range 30–53 years)
and they had been practising in oncology for a median of 10.1
years (range 1–29 years). The sample contained 20 male and 10
female clinicians. 
Clinicians who agreed to participate underwent a semi-
structured interview lasting between 30–40 minutes. The interview
schedule comprised 4 sections. 
Prescribing practice 
The oncologists were asked to report their standard first-line
chemotherapy (FLCT) and second-line chemotherapy (SLCT)
regimens, the side effects associated with these chemotherapeutic
agents and any circumstances under which they would not recom-
mend chemotherapy due to potential side effects. 
The goals of palliative chemotherapy 
Five key goals of palliative chemotherapy were identified through
a literature search and by means of questioning relevant experts.
These were prolongation of life, symptom relief, delaying the
onset of symptoms, improving patient activity and maintaining the
patient’s hope of a positive outcome. The goals were examined
within the framework of the SEU theory of decision-making. The
perceived effectiveness of the goals of palliative chemotherapy
comprised 2 questions. The clinicians were asked to rate on a 
4-point scale (not at all, a little, moderately, very effective) how
effective they thought chemotherapy would be in achieving each
of the goals. They then estimated on a 5-point scale (none, a few, a
moderate number, most, all) the proportion of patients that this
goal could be achieved in. The mean of these 2 responses was
taken as the perceived effectiveness (expectancy) score. The clini-
cians also rated (on a 10-point numerical scale) how valuable they
perceived each of the goals to be with regard to a woman with
advanced breast cancer. The clinician’s perception of the efficacy
of palliative chemotherapy may be influenced by the disease
progression (i.e. chemotherapy regimens may be perceived to be
less effective as the disease progresses) and therefore the same
perceived effectiveness questions were asked for both first- and
second-line chemotherapy. The value attached to each outcome
would not be expected to change in relation to disease progression,
as an outcome is either perceived as valuable or not. Therefore,
value questions were asked only once and were phrased in relation
to palliative chemotherapy. 
Both the perceived effectiveness and value scores were log
transformed so that each had a potential range of scores of 0 to
100. This was to ensure that the value scores (which had a higher
possible maximum score due to the greater range of the rating
scale for these questions) did not unduly influence the total SEU
score. As the value and perceived effectiveness scores were rated
on different scales it would not be appropriate to make a direct
comparison between them. The SEU scores were calculated as: 
(perceived effectiveness score ´ value score)/100. This gave a
potential range of 0 to 100. 
The importance of disease, treatment and patient
factors in offering palliative chemotherapy 
The importance of 10 disease- and treatment-related factors and 12
patient-related factors in decision-making regarding palliative
chemotherapy was assessed. The influential factors were identified
from a literature review and through discussion with relevant
experts (oncologists, palliative care specialists, psychologists and
a psychiatrist). Clinicians rated on a 4-point scale (not at all, a
little, quite, very) the importance of each factor in a decision to
give chemotherapy to a woman with advanced breast cancer for
whom there were no hormonal treatments which would be of
benefit. For the analysis this scale was collapsed to form 2 catego-
ries (1) not at all/a little, (2) quite/very. The number of clinicians
rating each factor in the 2 categories was calculated. The data
presented refer to the percentage of clinicians rating a particular
factor as quite/very important in the decision. 
Scenario of decision-making for a hypothetical patient 
The scenario examined which factors were important in the deci-
sion to recommend chemotherapy to a hypothetical patient with
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advanced breast cancer. This was felt to be more representative of
the clinical situation than reference to the ‘average patient’.
Clinicians rated on a 5-point scale (definitely not, possibly, prob-
ably, almost definitely, definitely) how likely they would be to
discuss and to recommend chemotherapy to a hypothetical patient
under varying conditions (see Appendix). 
The ratings were re-labelled 1 (definitely not) to 5 (definitely)
for the analysis. The baseline score was defined as the rating
obtained following the initial scenario. The scores obtained for
each subsequent condition were then calculated and the difference
between this score and baseline score was obtained. This differ-
ence score (for each of the 7 conditions) was plotted against the
baseline score to ascertain the effect of each condition on the initial
decision. 
Statistical analysis 
Medians and inter-quartile ranges (IQR) are reported. Differences
in the responses assigned to first- and to second-line chemotherapy
were examined using the Wilcoxon Signed Ranks test. The
Mann–Whitney U test was used to examine differences according
to speciality, grading and gender. 
RESULTS 
Prescribing practice 
The 3 most frequently reported standard first-line chemotherapy
regimes were fluorouracil, epirubicin and cyclophosphamide
(FEC) (reported by 59% of clinicians), cyclophosphamide,
methotrexate and fluorouacil (CMF) (31%) and mitozantrone,
mitomycin and methotrexate (MMM) (24%). For second-line
chemotherapy the most frequently cited standard regime was
paclitaxel (Taxol) (cited by 41% of clinicians), followed by MMM
(28%) and vinorelbine (21%). The most frequently reported side
effects for both first- (FLCT) and second-line chemotherapy
(SLCT) were alopecia (89% FLCT, 86% SLCT), nausea and
vomiting (83% FLCT, 72% SLCT), fatigue (66% FLCT, 45%
SLCT) and neutropenia (48% FLCT, 44% SLCT). The patient’s
preferences, performance status and frailty were the commonest
reasons for not prescribing chemotherapy due to potential side
effects. 
The estimated extra time a patient might expect with FLCT
(mean 4.9 months, SD 2.7) was significantly greater than the 2.9
months (SD 1.7) estimated for SLCT (Z = – 4.43, P < 0.05). The
medical oncologists were more optimistic regarding the extra time
afforded by FLCT (5.6 months, SD 2.0) than were the clinical
oncologists (4.3 months, SD 2.8) (Z = –2.04, P < 0.05). The 2
specialities were not significantly different in their estimates for
SLCT (Z = –1.50, P = 0.14). There were no significant differences
between the genders or grades (specialist registrar or consultant)
with regard to survival estimates. 
Goals of palliative chemotherapy 
Perceived effectiveness of the goals of palliative
chemotherapy 
The most achievable goals in relation to FLCT (see Table 1) were
viewed equally to be symptom relief, maintenance of hope and
improvement of activity (with a median rating of 57.1). The
overall ranking of the goals for SLCT was similar to that of FLCT,
except that improvement of activity received a lower comparative
rating. The perceived effectiveness scores for each of the 5 goals
assigned for SLCT were significantly lower than for first-line
chemotherapy (all P values < 0.01). 
Value of palliative chemotherapy 
The value questions were phrased in relation to palliative chemo-
therapy and did not examine FLCT and SLCT separately. The
value scores attached to each of the goals of chemotherapy
differed somewhat from the respective perceived effectiveness
scores (Table 1). Improvement of activity was rated as the most
valued goal of chemotherapy (median score 98.2) followed by
symptom relief (median score 70.3). However, maintenance of
hope was rated as the fourth most valuable use of palliative
chemotherapy, whereas it had been ranked as the most achievable
goal for both first- and second-line chemotherapy.
Although prolongation of life was only rated as the third most
valued goal of palliative chemotherapy further examination of the
data revealed that the value ratings were dependent upon of the
amount of extra time a woman could expect. Clinicians were asked
to indicate how valuable they believed it would be for a patient
with advanced breast cancer to have an extension of life of
between 1 and 24 months. The results are represented in Figure 1.
It can be seen that an extension of life of 12 months or more was
valued most highly and that there was greater agreement (less vari-
ability) among the clinicians regarding survival times of 18 and 24
months. A similar time-dependent pattern was apparent for ques-
tions relating to delaying the onset of symptoms although the clini-
cians continued to vary in their value ratings even with increasing
delay times (Figure 2). There were no significant differences in the
value scores assigned by the oncologists according to speciality,
gender or grading. 
Table 1 The median effectiveness (expectancy) and value (utility) scores assigned to each of
the potential goals of chemotherapy. The inter-quartile ranges are shown in parentheses 
Goal Median effectiveness score Median value score 
FLCT SLCT 
Prolongation of life 42.9 (28.6) 28.6 (3.6) 68.2 (11.9) 
Symptom relief 57.1 (14.3) 35.7 (28.6) 70.3 (15.2) 
Delaying onset of symptoms 46.4 (28.6) 0 (8.6) 53.3 (18.9) 
Improvement of activity 57.1 (16.1) 28.6 (14.3) 98.2 (14.8) 
Maintaining hope 57.1 (14.3) 42.9 (28.6) 66.7 (25.0) Decision making for palliative chemotherapy 1175
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Subjective expected utility (SEU) scores 
The SEU scores were calculated as the perceived effectiveness
score (for FLCT or SLCT) multiplied by the value score divided
by 100 (see Table 1 for the scores for the individual scales). The
median SEU scores for FLCT and SLCT are shown in Figure 3.
The highest SEU score in relation to FLCT was obtained for
improvement of activity (median 48.7, IQR 21.7). The median
score for symptom relief was slightly lower although there was
less variability in the rating of this goal (median 44.4, IQR 11.4).
Maintenance of hope was assigned the third highest SEU score 
(median 39.7, IQR 19.9), followed by prolongation of life (median
25.2, IQR 13.1) and finally, delaying the onset of symptoms 
(median 21.0, IQR 18.1). 
For SLCT the highest SEU score was obtained for maintenance
of hope (median 31.8, IQR 19.8) followed closely by improvement
of activity (median 28.6, IQR 15.3) and symptom relief (median
25.4, IQR 18.3). The 2 remaining goals were rated in the same
order as for FLCT; prolongation of life (median 17.7, IQR 8.6) and
delaying the onset of symptoms (median 0.0, IQR 12.7). SEU
scores for SLCT were significantly lower than for FLCT (Figure 3);
prolongation of life (Z = –3.91, P < 0.01), symptom relief (Z = 
– 4.26, P < 0.01), delaying symptoms (Z = – 4.20, P < 0.01),
improving activity (Z = –3.65, P < 0.01) and maintenance of hope
(Z = –3.77, P < 0.01). 
The only significant difference to emerge between the SEU
scores obtained from the clinical and medical oncologists was for
symptom relief in relation to FLCT. Clinical oncologists produced
significantly lower SEU scores for symptom relief than medical
oncologists (Z = –2.15, P < 0.05). There were no significant differ-
ences in the SEU scores according to oncologist’s grade or gender. 
Factors of importance in decision making regarding
palliative chemotherapy 
Three patient-related factors were most frequently reported to affect
the decision to recommend palliative chemotherapy (Table 2).
These were the patient’s current performance status, the patient’s
wish to receive/not receive chemotherapy and the frailty of the
patient. The disease/treatment-related factors rated as important
were the pace of the disease, previous response to chemotherapy and
the toxicity experienced, the presence of other symptoms/medical
problems and the site of the metastases. The factors rated as least
important in the decision to offer treatment were language barriers,
the patient’s education level and their access to transportation. 
A comparison of the responses of medical and clinical oncolo-
gists revealed that significantly more clinical oncologists rated the
site of the metastases (Z = – 0.716, P = 0.47) and the patient’s
previous response to chemotherapy (Z = – 0.694, P = 0.49) as
important in the decision. There were no significant differences
between the responses according to the clinician’s gender or
grading. 
Scenario of decision-making for a hypothetical patient 
Following the initial scenario 65% of clinicians indicated that they
would almost definitely or definitely discuss chemotherapy with
the patient. However, only 20% indicated they would actually
recommend chemotherapy to the patient. Several conditions were
found to differ significantly from the baseline measurement (using
the Wilcoxon Signed Ranks Test) suggesting that each might influ-
ence the original decision. Breathlessness (Z = –3.91, P < 0.05)
was found to increase the likelihood of the oncologist recom-
mending treatment. An increase in age of 20 years (Z = –2.45,
P < 0.01), concurrent illnesses (Z = –2.97, P < 0.05), adverse
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Prolongation of life
Figure 1 The median standardized value scores assigned to various
periods by which life could be extended (for a woman with metastatic breast
cancer). The dashed lines represent the total range of responses assigned to
each time period 
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previous experience of chemotherapy (Z = –3.30, P < 0.05) and
depression (Z = –3.54, P < 0.01) were shown to decrease the like-
lihood of the oncologist recommending chemotherapy (Figure 4). 
DISCUSSION 
There was a stronger belief among oncologists regarding the effec-
tiveness of FLCT and this reflects the greater response rates
published for FLCT rather than SLCT (Gregory et al, 1993;
Benner et al, 1994). The estimates of extra survival time provided
by the oncologists in this study are comparable with the 4 to 6
months for FLCT and 2 to 3 months for SLCT reported in the
literature (Benner et al, 1994; Leonard et al, 1995). 
The goals of palliative chemotherapy 
Both improvement of activity and symptom relief were rated as the
most valuable and achievable goals of palliative chemotherapy.
Improvement in symptoms is often associated with an observable
improvement in the patient’s physical functioning (Dodwell et al,
1993) which consequently may enable patients to carry out their
daily activities, an outcome highly valued by both patients and
clinicians (Sutherland et al, 1990; Dodwell et al, 1993). An objec-
tive response to chemotherapy (measured as a reduction in tumour
bulk) is associated with improvement in both symptoms and
performance status (Baum et al, 1980; Ramirez et al, 1998; Geels
et al, 2000) and therefore clinicians would perceive these 2 goals
as achievable. 
This study did not examine the influence of individual chemo-
therapeutic drugs on evaluations of the goals of palliative chemo-
therapy. It is probable that clinicians would consider whether the
likely response (i.e. a reduction in symptoms) would be great
enough to offset potential toxic effects. This discussion may be
particular relevant to the use of taxanes as SLCT agents, as certain
agents (i.e. docetaxel) are known to be associated with serious side
effects such as oedema with or without pleural effusion (Vogel and
Nabholtz, 1999). However, it is known that cancer patients are
prepared to undergo radical treatment even if this is only asso-
ciated with a potentially small reduction in symptoms or minimal
prolongation of life (Slevin et al, 1990). Currently a study is being
undertaking to examine both oncologists’ decision-making and
patients’ perceptions of treatment within clinical situations and
therefore information regarding actual clinical decisions should be
available at the end of the study. 
The clinicians reported that it was possible to maintain a
patient’s sense of hope through the prescription of chemotherapy.
Despite the low-value score assigned to this goal the high SEU
score suggested that it would probably be one of the main reasons
for prescribing second-line chemotherapy. Previous research has
suggested that European oncologists are less likely than their
American counterparts to perceive maintenance of hope as an
important part of palliative treatments (Maher et al, 1992) and our
results suggest that for first-line chemotherapy this may be so. 
Factors influencing decisions regarding palliative
chemotherapy 
Poor performance status and frailty were rated as very important 
in decisions to recommend chemotherapy, both of which have
previously been identified as indicators of poor outcome from
Table 2 The percentage of clinicians rating each factor as quite or very important in the decision to give palliative
chemotherapy to a woman with metastatic breast cancer. The factors are grouped according to patient and tumour-related
factors 
%%  
Tumour/treatment-related factors of responses Patient-related factors of responses 
Pace of disease 89.7 Performance status 96.6 
Previous response to chemotherapy 86.2 Patient’s wishes 96.6 
Symptoms other than pain 86.2 Frailty 93.1 
Concurrent medical conditions 82.8 Age 58.6 
Site of metastases 79.3 Social support 51.7 
Toxicity with previous chemotherapy 79.3 Anxiety 44.8 
Pain 55.2 Depression 44.8 
Previous response to hormone therapy 37.9 Patient’s family’s wishes 37.9 
ER/PR status 27.6 Pre-morbid personality 27.6 
Histological type/grade 24.1 Language barriers 20.7 
Education level 13.8 
Access to transportation 10.3 
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chemotherapy (Rubens et al, 1992). This study’s identification of
several primary patient-related factors is not in agreement with
previous studies that have highlighted the importance of
tumour/treatment factors (Derber and Thompson, 1990; McGuire
et al, 1991). This may, however, reflect the different methodolo-
gies employed; the current study presented both disease- and
patient-related factors whereas previous studies have placed
greater reliance on tumour/treatment factors as this information is
routinely requested by clinicians. 
Within the decision-making scenarios, being older, having a
concurrent medical condition, having had a difficult previous
experience of chemotherapy, being depressed and the patient’s
future plans were all found to decrease the likelihood of clinicians
recommending chemotherapy. All these factors affect patients’
tolerance to treatment and possibly the outcome of treatment
(Rubens et al, 1992). Breathlessness, however, was shown to
increase the likelihood of the oncologist recommending chemo-
therapy. This factor relates to the goal of symptom relief which
was viewed as an achievable goal of chemotherapy by the clini-
cians. 
The present study elicited important information regarding
oncologists’ perceptions of the goals of palliative chemotherapy
and the factors they consider when making decisions regarding the
treatment of patients with advanced breast cancer. The SEU model
provided a good starting point from which to investigate
oncologists’ treatment-based decision-making regarding women
with advanced breast cancer. By examining expectancy (perceived
effectiveness) and value separately it has allowed us to demon-
strate that even though some of the goals (e.g. maintenance of
hope) are not highly valued by oncologists, these goals may be
perceived as easy to achieve and therefore chemotherapy may be
prescribed for this purpose. The study, however, relied on general-
ized questions and hypothetical scenarios to elicit this information
and therefore responses may not reflect actual clinical practice.
This may also explain why few differences were found between
the different clinical specialities and grades. A study is currently
being undertaken to examine oncologists’ decision-making with
individual patients in clinical situations. 
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APPENDIX 
Scenario of decision-making for a hypothetical patient 
A 48-year-old woman was initially diagnosed at another hospital with a 3 cm, 2 lymph node positive, grade III ductal carcinoma 4 years
ago. She underwent breast conserving therapy including tumorectomy, axillary clearance and radiotherapy to the breast. She then received
6 cycles of standard adjuvant CMF with tamoxifen. Her periods stopped during chemotherapy. Recurrence was first detected in the suprac-
lavicular fossa 6 months ago. She was treated with radiotherapy and her hormonal treatment was changed to anastrozole (Arimidex). She
recently had a chest infection that has now cleared. However, a chest X-ray was undertaken which shows small pulmonary nodules highly
suggestive of metastatic disease. She is said to be asymptomatic. She is now being referred to you for further management. You have never
met the patient, but are aware of this information prior to the consultation. 
The following conditions are then introduced. After each condition the clinician was asked to refer back to the original scenario (so the
conditions were not additive). 
1. You now learn that the patient is breathless. 
2. The woman is 68 years old, rather than 48 years old. 
3. When you meet the patient, she is in a wheel chair and tells you that she has been house-bound by multiple sclerosis for the past 10
years. 
4. The patient tells you that she lives alone and has no support at all. 
5. The patient tells you that the adjuvant CMF was the worst experience of her life. 
6. The patient tells you that she is feeling low, almost to the point of wanting to end her life. 
7. The patient tells you that she is determined to be well enough to visit her daughter in Canada for Christmas in 6 months time. 